GAITHERSBURG, Md., August 27, 2025 – The U.S. Food and Drug Administration (FDA) has granted approval for Novavax’s Nuvaxovid™ 2025–2026 Formula, marking it as the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the upcoming vaccination season. The vaccine is authorized for use in individuals 65 years and older and in patients aged 12–64 with underlying medical conditions that increase their risk of severe outcomes from COVID-19. This decision provides an important new option ahead of the fall immunization campaign.
Science Significance
Nuvaxovid represents a scientifically distinct approach to COVID-19 prevention. Unlike mRNA vaccines, it uses recombinant nanoparticle technology to produce a copy of the SARS-CoV-2 spike protein, combined with the Matrix-M® adjuvant to enhance immune response. Clinical and preclinical data demonstrate its safety and efficacy, particularly against the JN.1 variant, which accounts for the majority of global infections as of July 2025. Importantly, the vaccine has shown immune coverage across multiple JN.1 lineage strains, including NB.1.8.1, LP.8.1, XFG, XFC, LF.7, and XEC.
Regulatory Significance
The FDA’s approval underscores confidence in protein-based vaccine technology and expands options beyond mRNA. By addressing post-pandemic needs for broader vaccine platforms, this decision reflects the regulator’s commitment to ensuring vaccine diversity, safety, and long-term preparedness. The authorization is also aligned with CDC guidance on myocarditis and pericarditis monitoring, emphasizing robust post-market safety oversight.
Business Significance
Advertisement
For Novavax, the approval is a major business milestone. Through its partnership with Sanofi, which is leading commercialization efforts, the company is positioned to expand access while receiving tiered royalties on vaccine sales. This not only strengthens Novavax’s revenue outlook but also validates its Matrix-M® technology platform as a differentiator in the competitive vaccine market. The move highlights Novavax’s strategy to grow through partnerships, portfolio expansion, and global supply chain leverage.
Patients’ Significance
For patients, the vaccine provides a valuable alternative. Individuals who may be hesitant about or medically contraindicated for mRNA vaccines now have access to a protein-based solution with a well-established safety and tolerability profile. Its formulation in pre-filled syringes, with storage at 2–8°C, ensures ease of distribution and accessibility, particularly through existing vaccination infrastructure.
Policy Significance
On a policy level, the FDA’s approval strengthens U.S. pandemic preparedness by diversifying vaccine platforms. By authorizing a non-mRNA option, regulators ensure that public health strategies are inclusive of different populations and patient preferences. This decision may also influence global regulatory bodies, reinforcing the role of protein-based vaccines in long-term COVID-19 management.
Transaction Highlights
The approval triggers a commercialization pathway led by Sanofi, with Novavax benefiting from royalty streams on sales. The vaccine’s variant-specific formulation, combined with its stability in existing cold chain systems, enhances its market readiness. For investors, the milestone supports Novavax’s growth trajectory while underscoring the value of its technology platform and licensing model.
Source: Novavax, Inc. Press Release
